{"gene":"DMD","run_date":"2026-06-09T23:54:42","timeline":{"discoveries":[{"year":1989,"finding":"Frameshift deletions in the DMD gene result in more severe (Duchenne) phenotype than in-frame deletions, which result in milder (Becker) phenotype. This 'reading frame rule' was established by correlating deletion endpoints (determined by genomic probes) with clinical phenotype in 80 unrelated patients.","method":"Genomic deletion mapping with cDNA probes and clinical phenotype correlation in 80 patients","journal":"American journal of human genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — large cohort genotype-phenotype correlation replicated across multiple labs, foundational reading frame rule established","pmids":["2491010"],"is_preprint":false},{"year":2004,"finding":"The H19 differentially methylated domain (DMD) acts as a maternal-specific, methylation-sensitive insulator by binding CTCF on the maternal allele. CpG mutations in the DMD repeats that retain CTCF-binding and enhancer-blocking activity disrupted maintenance of paternal DMD methylation in vivo, demonstrating that CpG content of the repeats is required for methylation maintenance but is antagonistic to insulator assembly. NOTE: This paper concerns the H19-Igf2 imprinting control region DMD (differentially methylated domain), not the dystrophin protein-coding DMD gene.","method":"CpG point mutagenesis of the H19 DMD in mice, maternal/paternal inheritance analysis, reporter gene expression","journal":"Nature genetics","confidence":"Low","confidence_rationale":"Tier 1 / Strong — rigorous in vivo mutagenesis, but this paper concerns the H19 imprinting locus 'DMD', not the dystrophin gene; excluded from canonical protein mechanism","pmids":["15273688"],"is_preprint":false},{"year":2007,"finding":"Duplication mutations in the DMD gene arise predominantly near the 5' end of the gene (exon 2 being the most common single duplication), and sequencing of breakpoints showed they do not arise from unequal sister chromatid exchange but more likely from synthesis-dependent nonhomologous end joining, indicating a distinct mutational mechanism from deletions.","method":"MLPA, breakpoint sequencing, analysis of 118 DMD duplications","journal":"Human mutation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — breakpoint sequencing in 118 cases from a single study, two orthogonal methods","pmids":["16917894"],"is_preprint":false},{"year":2007,"finding":"Transgenic mice carrying the intact full-length human DMD gene (hDMD) express all dystrophin isoforms in a tissue-specific pattern consistent with the endogenous gene. The hDMD transgene rescued the lethal dystrophic phenotype of mdx x utrophin-null mice, demonstrating functional competence of the human genomic locus in vivo.","method":"Yeast artificial chromosome fusion, transgenic mouse generation, RT-PCR, Western blotting, histological analysis, genetic rescue of mdx x Utrn-/- mice","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — functional in vivo rescue of lethal phenotype with full-length human gene, multiple orthogonal validation methods","pmids":["18083704"],"is_preprint":false},{"year":2009,"finding":"Duplications in the DMD gene can produce aberrant transcripts that do not follow simple reading-frame predictions; RNA analysis revealed that exon-skipping events occurring within duplicated regions can re-establish the reading frame in some BMD patients carrying out-of-frame duplications, while an in-frame duplication can cause DMD through post-transcriptional/translational mechanisms not explained by the reading frame rule.","method":"RNA analysis (RT-PCR) of duplicated DMD transcripts in 16 patients","journal":"Human mutation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct RNA analysis in patients, single lab, two orthogonal findings","pmids":["18853462"],"is_preprint":false},{"year":2013,"finding":"The DMD gene is more highly expressed in heart than in skeletal muscle. Transcript stability (rather than transcriptional rate) is an important determinant of dystrophin protein levels in Becker muscular dystrophy patients. The mdx mouse mutant transcript shows a 5' to 3' imbalance compared to wild-type, and antisense-mediated exon skipping does not correct this imbalance.","method":"RT-PCR quantification, Western blotting, antisense exon-skipping experiments in mice and human patients","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple methods (RT-PCR, Western blot, exon skipping experiments), single lab","pmids":["23975932"],"is_preprint":false},{"year":2013,"finding":"DMD point mutations can alter splicing regulatory elements (exonic splicing silencers/enhancers) to cause exon skipping, modifying disease severity. Nonsense and frameshift point mutations can produce aberrant splicing in 27/98 analyzed cases. Bioinformatics analysis showed the splicing pathway is highly dependent on the interplay between splice site strength and density of regulatory elements.","method":"RNA analysis of muscle mRNA, dystrophin protein expression, bioinformatics analysis of splicing signals in 98 DMD point mutation patients","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct mRNA analysis in patient samples, large cohort, single lab","pmids":["23536893"],"is_preprint":false},{"year":2015,"finding":"FUSE binding protein 1 (FUBP1) promotes recognition of endogenous DMD exon 39 in muscle cells by binding to an intronic splicing enhancer (ISE) in intron 38. RNase-assisted pulldown with mass spectrometry revealed that hnRNPA1, hnRNPA2/B1, and DAZAP1 are recruited to a mutant RNA probe and act as splicing repressors of exon 39. FUBP1 binding to the ISE RNA was confirmed by RNA pulldown, RNA EMSA, and RNA-ChIP on endogenous DMD pre-mRNA.","method":"RNase-assisted RNA pulldown with mass spectrometry, minigene splicing assays, RNA EMSA, RNA-ChIP, serial deletion and mutagenesis","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple orthogonal methods (pulldown-MS, EMSA, RNA-ChIP, mutagenesis) in a single rigorous study identifying mechanism of DMD pre-mRNA splicing regulation","pmids":["25662218"],"is_preprint":false},{"year":2016,"finding":"Endogenous multiple exon skipping (MES) products are present in normal human skeletal muscle RNA around the exon 44-56 region of the DMD gene. The 5' splice sites of post-transcriptional introns act as splicing donor sites for MES events. Upstream post-transcriptional introns trigger MES and generate circular RNAs (circRNAs) via back-splicing, consistent with the circRNA generation model.","method":"RT-PCR of total RNA from normal skeletal muscle, identification and sequencing of MES products, circular RNA analysis","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct RNA analysis in human tissue, single lab, multiple orthogonal findings","pmids":["27754374"],"is_preprint":false},{"year":2017,"finding":"DMD pre-mRNA splicing requires multi-step events for removal of long introns, involving temporary intron retention and co-transcriptional mechanisms. The large size of DMD introns necessitates recursive (multi-step) splicing, and alternative splicing can serve as a disease modifier by changing the outcome of primary mutations.","method":"Review synthesizing RNA sequencing data and splicing studies on human skeletal muscle DMD pre-mRNA","journal":"Human genetics","confidence":"Low","confidence_rationale":"Tier 3 / Weak — review paper summarizing experimental findings from multiple sources, no single direct experiment described in this abstract","pmids":["28597072"],"is_preprint":false},{"year":2019,"finding":"Dp71, the short dystrophin isoform expressed from a promoter in DMD intron 62, plays an essential role in tumor cell proliferation and clonogenicity in soft-tissue sarcomas. Dp71 inhibition by shRNA dramatically reduced cell proliferation and clonogenicity by altering cell cycle progression through G2/M phase, whereas Dp427 depletion had no effect on cell growth or migration.","method":"shRNA knockdown of Dp71 in STS cell lines, cell proliferation and clonogenicity assays, cell cycle analysis, RNA sequencing","journal":"Cancers","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function with defined cell cycle phenotype in three STS cell lines, single lab","pmids":["31266185"],"is_preprint":false},{"year":2019,"finding":"DMD cardiomyocyte-secreted exosomes (DMD-exo) promote pathological vulnerability to stress in DMD cardiomyocytes. The microRNA cargo (not surface peptides) of DMD-exo was implicated in pathological effects, with DMD-exo miRNA cargo regulating injurious pathways including p53 and TGF-beta. Non-affected exosomes were protective, while DMD-exo were not, and inhibition of DMD-exo secretion in vitro and in vivo improved stress response.","method":"iPSC-derived cardiomyocytes, exosome isolation and characterization, miRNA cargo profiling, transcriptomic profiling, ROS measurement, mitochondrial membrane potential assay, in vivo exosome secretion inhibition","journal":"Disease models & mechanisms","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods in iPSC-derived cardiomyocytes and in vivo, single lab","pmids":["33188007"],"is_preprint":false},{"year":2019,"finding":"Sarcospan (SSPN) overexpression restores cardiac sarcolemma stability in dystrophin-deficient mdx mice. SSPN interacts with dystrophin and utrophin at the sarcolemma and, when overexpressed, enhances fully glycosylated α-dystroglycan abundance, restores sarcolemmal stability (primary defect in DMD), reduces fibrosis, and improves cardiac contractile function and β-adrenergic responsiveness.","method":"SSPN transgenic mice crossed to mdx and mdx:utr-heterozygous backgrounds, echocardiography, hemodynamic pressure-volume analysis, histology, biochemical analysis","journal":"JCI insight","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple cardiac functional readouts in transgenic animal model, single lab, mechanistic link to sarcolemma stability","pmids":["31039133"],"is_preprint":false},{"year":2019,"finding":"In a canine DMD model with dystrophin deficiency (CXMD), inactivating mutations in the DMD gene occur frequently, and DMD is recurrently somatically mutated/deleted in canine osteosarcoma (50% of tumors). This suggests a tumor suppressor role for dystrophin beyond myogenic tissues.","method":"Whole genome sequencing and whole exome sequencing of 59 canine osteosarcoma tumors with matched normal tissue","journal":"Communications biology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — genomic sequencing study, no direct functional experiment on the DMD protein mechanism","pmids":["31341965"],"is_preprint":false},{"year":2019,"finding":"A tandem duplication involving DMD exons 2-7 inserted into intron 7 of the wild-type DMD gene in Labrador retrievers results in dystrophin non-detectable by Western blot and immunohistochemistry, but α-dystroglycan is present at essentially normal levels, indicating that α-dystroglycan membrane localization does not absolutely require dystrophin in this model.","method":"Whole genome sequencing, skeletal muscle cDNA analysis, Western blotting for dystrophin and α-dystroglycan, immunohistochemistry","journal":"Neuromuscular disorders : NMD","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct protein biochemistry (Western blot) in a natural animal model with defined mutation, single report","pmids":["36041985"],"is_preprint":false},{"year":2019,"finding":"The Dp116 isoform of dystrophin, expressed from a promoter in DMD intron 55, is expressed in glioblastoma cells. Two novel splicing patterns of DMD exons within the Dp116 region were identified: deletion of exons 68-69 and a 5' cryptic splice acceptor in exon 75, in addition to the predominant Dp116b variant lacking exon 78.","method":"PCR amplification of full-length Dp116 cDNA from U-251 glioblastoma cells, Western blotting, cDNA sequencing","journal":"Biochemistry and biophysics reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct RT-PCR and Western blot characterization of isoform expression, novel splice variants identified by sequencing, single lab","pmids":["31737793"],"is_preprint":false},{"year":2020,"finding":"Premature termination codons (PTCs) in the DMD gene reduce local DMD mRNA synthesis through a transcriptional (not NMD-based cytoplasmic) mechanism. NMD inhibition did not normalize DMD expression. In situ hybridization showed DMD mRNA localizes primarily in the nuclear compartment, ruling out cytoplasmic NMD. Nascent RNA sequencing revealed lower transcription rate in patient-derived myotubes. Chromatin immunoprecipitation showed increased H3K9me3 (repressive histone mark) at the DMD locus in mdx mice, and HDAC inhibitor givinostat increased DMD transcript expression in mdx mice.","method":"NMD inhibition assay, in situ hybridization, nascent RNA sequencing, chromatin immunoprecipitation (ChIP) for H3K9me3, HDAC inhibitor treatment in mdx mice","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple orthogonal methods (NMD inhibition, in situ hybridization, nascent RNA-seq, ChIP, pharmacological rescue) in a single study establishing epigenetic mechanism","pmids":["32616572"],"is_preprint":false},{"year":2021,"finding":"Noncoding (deep intronic) DMD variants cause splice-altering events leading to premature stop codons and nonsense-mediated mRNA decay. Quantitative Western blot correlated wild-type dystrophin levels with clinical severity: 0-5% dystrophin confers Duchenne phenotype, ~10% confers Becker phenotype, and ~15% is associated with myalgia without manifesting weakness.","method":"Whole-genome sequencing, muscle RNA-seq, PCR of muscle cDNA, quantitative Western blot for dystrophin","journal":"Neurology. Genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — quantitative Western blot linked to clinical phenotype in multiple families, single lab, consistent with prior literature","pmids":["33977140"],"is_preprint":false},{"year":2023,"finding":"Loss of full-length dystrophin isoform in hiPSC-derived cardiac fibroblasts from DMD patients results in deficient formation of actin microfilaments and a metabolic switch from mitochondrial oxidation to glycolysis. This metabolic remodeling is associated with an exacerbated myofibroblast phenotype and increased fibroblast activation in response to pro-fibrotic challenges.","method":"hiPSC-derived cardiac fibroblasts from DMD patients, immunofluorescence for actin microfilaments, mitochondrial respiration assay (Seahorse), glycolysis measurement, myofibroblast activation assay","journal":"Biology direct","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (cytoskeletal, metabolic, phenotypic assays) in patient-derived cells, single lab","pmids":["37501163"],"is_preprint":false},{"year":2023,"finding":"In DMD skeletal muscle, fibro-adipogenic progenitor (FAP) content increases concurrently with a decline in muscle regenerative capacity. DMD muscle stem cells acquire a senescence phenotype early in the disease course, and this senescence correlates with impaired satellite cell activation and expansion.","method":"Myopathologic analysis of 24 DMD patient muscle biopsies, immunostaining and histology for FAPs, satellite cells, and senescence markers","journal":"Acta neuropathologica communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct histopathological analysis in patient biopsies with cellular mechanistic readouts, single lab","pmids":["37858263"],"is_preprint":false}],"current_model":"The DMD gene encodes dystrophin, a large cytoskeletal protein whose absence (caused by frame-disrupting mutations) leads to loss of sarcolemmal stability; the reading frame rule governs phenotypic severity (frameshift = Duchenne, in-frame = Becker), with transcript stability and chromatin-level epigenetic repression (H3K9me3) further determining residual dystrophin levels; pre-mRNA splicing of the large DMD transcript involves co-transcriptional recursive splicing regulated by intronic enhancers bound by FUBP1 and repressors including hnRNPA1/A2B1; the short Dp71 isoform has an independent role in cell cycle progression in non-muscle cells; and dystrophin deficiency in cardiomyocytes propagates pathological signals via exosomal miRNA cargo, while loss of full-length dystrophin in cardiac fibroblasts disrupts actin microfilaments and drives metabolic reprogramming toward glycolysis with a pro-fibrotic phenotype."},"narrative":{"mechanistic_narrative":"The DMD gene encodes dystrophin, a cytoskeletal protein required for sarcolemmal stability whose loss underlies Duchenne and Becker muscular dystrophy [PMID:2491010, PMID:31039133]. Frame-disrupting mutations follow a reading-frame rule in which frameshift deletions cause severe Duchenne phenotypes while in-frame deletions cause milder Becker disease [PMID:2491010], and residual dystrophin levels quantitatively track clinical severity, with 0–5% conferring Duchenne, ~10% Becker, and ~15% only myalgia [PMID:33977140]. The functional competence of the full-length human locus is established by transgenic rescue of the lethal mdx × utrophin-null dystrophic phenotype [PMID:18083704]. At the membrane, dystrophin acts with sarcospan and utrophin to maintain glycosylated α-dystroglycan and sarcolemmal integrity, the primary defect in DMD, with sarcospan overexpression restoring cardiac stability and contractile function in dystrophin-deficient hearts [PMID:31039133]. The exceptionally large DMD pre-mRNA undergoes multi-step recursive, co-transcriptional splicing in which intronic enhancers recruit FUBP1 to promote exon recognition while hnRNPA1, hnRNPA2/B1 and DAZAP1 act as splicing repressors [PMID:25662218], and splicing outcomes — including point-mutation-induced exon skipping and endogenous multiple-exon-skipping that generates circular RNAs — serve as disease modifiers [PMID:23536893, PMID:27754374]. Beyond splicing, dystrophin expression is regulated transcriptionally and epigenetically: premature termination codons reduce nascent transcription rather than triggering cytoplasmic NMD, accompanied by repressive H3K9me3 deposition at the locus that is relieved by HDAC inhibition [PMID:32616572]. Internal promoters generate shorter isoforms with distinct roles, including Dp71, which drives sarcoma cell proliferation through G2/M cell cycle progression [PMID:31266185]. Dystrophin deficiency also has non-myofiber consequences: cardiomyocyte-secreted exosomal miRNA cargo propagates pathological stress signaling via p53 and TGF-β pathways [PMID:33188007], cardiac fibroblasts lose actin microfilaments and undergo a glycolytic, pro-fibrotic metabolic switch [PMID:37501163], and muscle stem cells acquire early senescence with expansion of fibro-adipogenic progenitors [PMID:37858263].","teleology":[{"year":1989,"claim":"Established the genotype-phenotype logic of DMD by showing that whether a deletion preserves the translational reading frame, not its size, determines disease severity.","evidence":"Genomic deletion mapping with cDNA probes correlated to clinical phenotype in 80 patients","pmids":["2491010"],"confidence":"High","gaps":["Does not explain exceptions where in-frame mutations cause severe disease","No molecular mechanism for how truncated protein retains partial function"]},{"year":2007,"claim":"Resolved the mutational origin of DMD duplications, showing they cluster at the 5' end and arise by synthesis-dependent nonhomologous end joining rather than unequal sister chromatid exchange.","evidence":"MLPA and breakpoint sequencing of 118 DMD duplications","pmids":["16917894"],"confidence":"Medium","gaps":["Single-study cohort","Does not link breakpoint mechanism to phenotypic outcome"]},{"year":2007,"claim":"Demonstrated that the full-length human DMD genomic locus is functionally competent in vivo, rescuing the lethal dystrophic phenotype and providing a humanized model.","evidence":"Full-length hDMD transgenic mouse, genetic rescue of mdx × Utrn-/- mice with RT-PCR, Western blot, histology","pmids":["18083704"],"confidence":"High","gaps":["Does not dissect individual isoform contributions to rescue","No quantitative threshold for rescue established"]},{"year":2009,"claim":"Revealed exceptions to the reading-frame rule by showing that exon-skipping within duplications can restore frame and that in-frame duplications can still cause disease through post-transcriptional mechanisms.","evidence":"RT-PCR RNA analysis of duplicated DMD transcripts in 16 patients","pmids":["18853462"],"confidence":"Medium","gaps":["Small patient number","Post-transcriptional mechanism for in-frame duplication pathogenicity not defined"]},{"year":2013,"claim":"Identified transcript stability and splicing-regulatory point mutations as quantitative determinants of dystrophin levels beyond simple frame prediction.","evidence":"RT-PCR, Western blot, exon-skipping in mdx/patients; RNA and bioinformatic splicing analysis of 98 point-mutation patients","pmids":["23975932","23536893"],"confidence":"Medium","gaps":["Mechanism controlling transcript stability not identified","Splicing predictions not validated for all mutation classes"]},{"year":2015,"claim":"Defined the protein machinery of DMD pre-mRNA splicing, identifying FUBP1 as an intronic-enhancer-bound activator of exon recognition antagonized by hnRNP repressors.","evidence":"RNase-assisted pulldown-MS, minigene assays, RNA EMSA, RNA-ChIP, mutagenesis on endogenous DMD pre-mRNA","pmids":["25662218"],"confidence":"High","gaps":["Studied at a single exon (exon 39); generality across the transcript unknown","How these factors are deployed across recursive splicing not addressed"]},{"year":2016,"claim":"Showed that endogenous multiple-exon-skipping and back-splicing generate circular RNAs from the DMD transcript, revealing complexity in normal DMD processing.","evidence":"RT-PCR and sequencing of MES products and circRNAs from normal human skeletal muscle","pmids":["27754374"],"confidence":"Medium","gaps":["Function of DMD circRNAs unknown","Single-tissue analysis"]},{"year":2020,"claim":"Overturned the assumption that nonsense mutations act only via cytoplasmic NMD, showing instead a transcriptional/epigenetic mechanism marked by H3K9me3 that is pharmacologically reversible.","evidence":"NMD inhibition, in situ hybridization, nascent RNA-seq, H3K9me3 ChIP, givinostat treatment in mdx mice","pmids":["32616572"],"confidence":"High","gaps":["Mechanism linking PTC to chromatin repression not defined","Whether givinostat-induced transcript yields functional protein not shown"]},{"year":2021,"claim":"Quantified the dystrophin-level thresholds separating Duchenne, Becker, and asymptomatic-myalgia phenotypes, and showed deep-intronic variants cause disease via splice-altering NMD.","evidence":"Whole-genome sequencing, muscle RNA-seq, cDNA PCR, quantitative Western blot across families","pmids":["33977140"],"confidence":"Medium","gaps":["Thresholds derived from limited families","Does not address tissue-specific level requirements"]},{"year":2019,"claim":"Established roles for dystrophin and its isoforms beyond myofiber structure, including Dp71-driven sarcoma proliferation, exosomal miRNA-mediated cardiac stress signaling, and sarcospan-dependent sarcolemmal stabilization.","evidence":"shRNA Dp71 knockdown with cell-cycle/RNA-seq analysis; iPSC-cardiomyocyte exosome and miRNA profiling with in vivo inhibition; SSPN transgenic mdx cardiac functional analysis","pmids":["31266185","33188007","31039133"],"confidence":"Medium","gaps":["Dp71 cell-cycle mechanism molecularly undefined","Specific causal exosomal miRNAs not pinpointed","Sarcospan findings are overexpression-based"]},{"year":2023,"claim":"Extended DMD pathology to non-myofiber cell types, showing dystrophin loss drives cardiac fibroblast metabolic reprogramming/fibrosis and muscle stem-cell senescence with FAP expansion.","evidence":"hiPSC-derived cardiac fibroblast cytoskeletal/metabolic assays; myopathologic and immunostaining analysis of 24 patient muscle biopsies","pmids":["37501163","37858263"],"confidence":"Medium","gaps":["Causal link between actin loss and glycolytic switch not mechanistically resolved","Senescence trigger in stem cells unidentified","Single-lab patient cohorts"]},{"year":null,"claim":"How dystrophin isoform-specific functions, recursive co-transcriptional splicing, epigenetic repression, and non-myofiber pathology integrate into a unified disease mechanism remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model of dystrophin in the sarcolemmal complex from the corpus","Molecular partners of short isoforms in non-muscle cells unmapped","Whether transcript-level interventions restore functional protein at disease thresholds untested"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0008092","term_label":"cytoskeletal protein binding","supporting_discovery_ids":[12,18]},{"term_id":"GO:0005198","term_label":"structural molecule activity","supporting_discovery_ids":[3,12]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[12,14]},{"term_id":"GO:0005856","term_label":"cytoskeleton","supporting_discovery_ids":[18]}],"pathway":[],"complexes":["dystrophin-glycoprotein complex"],"partners":["SSPN","UTRN","FUBP1","HNRNPA1","HNRNPA2B1","DAZAP1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P11532","full_name":"Dystrophin","aliases":[],"length_aa":3685,"mass_kda":426.8,"function":"Anchors the extracellular matrix to the cytoskeleton via F-actin. Ligand for dystroglycan. Component of the dystrophin-associated glycoprotein complex which accumulates at the neuromuscular junction (NMJ) and at a variety of synapses in the peripheral and central nervous systems and has a structural function in stabilizing the sarcolemma. Also implicated in signaling events and synaptic transmission","subcellular_location":"Cell membrane, sarcolemma; Cytoplasm, cytoskeleton; Postsynaptic cell membrane","url":"https://www.uniprot.org/uniprotkb/P11532/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/DMD","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/DMD","total_profiled":1310},"omim":[{"mim_id":"620941","title":"SYNAPTOPODIN 2; SYNPO2","url":"https://www.omim.org/entry/620941"},{"mim_id":"619994","title":"DYNEIN LIGHT CHAIN, TCTEX-TYPE FAMILY, MEMBER 5; DYNLT5","url":"https://www.omim.org/entry/619994"},{"mim_id":"619040","title":"MYOFIBRILLAR MYOPATHY 10; MFM10","url":"https://www.omim.org/entry/619040"},{"mim_id":"618510","title":"DYSTROTELIN; DYTN","url":"https://www.omim.org/entry/618510"},{"mim_id":"617683","title":"EGF-LIKE, FIBRONECTIN TYPE III, AND LAMININ G DOMAINS-CONTAINING PROTEIN; EGFLAM","url":"https://www.omim.org/entry/617683"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in many","driving_tissues":[],"url":"https://www.proteinatlas.org/search/DMD"},"hgnc":{"alias_symbol":["BMD","DXS142","DXS164","DXS206","DXS230","DXS239","DXS268","DXS269","DXS270","DXS272"],"prev_symbol":["MRX85"]},"alphafold":{"accession":"P11532","domains":[],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P11532","model_url":"https://alphafold.ebi.ac.uk/files/AF-P11532-9-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P11532-9-F1-predicted_aligned_error_v6.png","plddt_mean":76.38},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=DMD","jax_strain_url":"https://www.jax.org/strain/search?query=DMD"},"sequence":{"accession":"P11532","fasta_url":"https://rest.uniprot.org/uniprotkb/P11532.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P11532/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P11532"}},"corpus_meta":[{"pmid":"19937601","id":"PMC_19937601","title":"Mutational spectrum of DMD mutations in dystrophinopathy patients: application of modern diagnostic techniques to a large cohort.","date":"2009","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/19937601","citation_count":263,"is_preprint":false},{"pmid":"2491010","id":"PMC_2491010","title":"Molecular and phenotypic analysis of patients with deletions within the deletion-rich region of the Duchenne muscular dystrophy (DMD) gene.","date":"1989","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/2491010","citation_count":176,"is_preprint":false},{"pmid":"21468001","id":"PMC_21468001","title":"Current status of pharmaceutical and genetic therapeutic approaches to treat DMD.","date":"2011","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/21468001","citation_count":149,"is_preprint":false},{"pmid":"27343068","id":"PMC_27343068","title":"DMD genotypes and loss of ambulation in the CINRG Duchenne Natural History Study.","date":"2016","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/27343068","citation_count":145,"is_preprint":false},{"pmid":"16030524","id":"PMC_16030524","title":"Deletion and duplication screening in the DMD gene using MLPA.","date":"2005","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/16030524","citation_count":139,"is_preprint":false},{"pmid":"2072118","id":"PMC_2072118","title":"Serum creatine-kinase (CK) and pyruvate-kinase (PK) activities in Duchenne (DMD) as compared with Becker (BMD) muscular dystrophy.","date":"1991","source":"Journal of the neurological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/2072118","citation_count":124,"is_preprint":false},{"pmid":"16917894","id":"PMC_16917894","title":"Duplications in the DMD gene.","date":"2006","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/16917894","citation_count":120,"is_preprint":false},{"pmid":"20630757","id":"PMC_20630757","title":"Clinical and genetic characterization of manifesting carriers of DMD mutations.","date":"2010","source":"Neuromuscular disorders : NMD","url":"https://pubmed.ncbi.nlm.nih.gov/20630757","citation_count":120,"is_preprint":false},{"pmid":"26284620","id":"PMC_26284620","title":"DMD Mutations in 576 Dystrophinopathy Families: A Step Forward in Genotype-Phenotype Correlations.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26284620","citation_count":115,"is_preprint":false},{"pmid":"29479480","id":"PMC_29479480","title":"Humanizing the mdx mouse model of DMD: the long and the short of it.","date":"2018","source":"NPJ Regenerative medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29479480","citation_count":110,"is_preprint":false},{"pmid":"15273688","id":"PMC_15273688","title":"Antagonism between DNA hypermethylation and enhancer-blocking activity at the H19 DMD is uncovered by CpG mutations.","date":"2004","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15273688","citation_count":95,"is_preprint":false},{"pmid":"31341965","id":"PMC_31341965","title":"Canine osteosarcoma genome sequencing identifies recurrent mutations in DMD and the histone methyltransferase gene SETD2.","date":"2019","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/31341965","citation_count":86,"is_preprint":false},{"pmid":"18083704","id":"PMC_18083704","title":"Generation and characterization of transgenic mice with the full-length human DMD gene.","date":"2007","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18083704","citation_count":73,"is_preprint":false},{"pmid":"17124406","id":"PMC_17124406","title":"Copy number variation in the genome; the human DMD gene as an example.","date":"2006","source":"Cytogenetic and genome research","url":"https://pubmed.ncbi.nlm.nih.gov/17124406","citation_count":69,"is_preprint":false},{"pmid":"25935002","id":"PMC_25935002","title":"Second-generation compound for the modulation of utrophin in the therapy of DMD.","date":"2015","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25935002","citation_count":68,"is_preprint":false},{"pmid":"18646569","id":"PMC_18646569","title":"Optimizing exon skipping therapies for DMD.","date":"2007","source":"Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology","url":"https://pubmed.ncbi.nlm.nih.gov/18646569","citation_count":63,"is_preprint":false},{"pmid":"9626497","id":"PMC_9626497","title":"Dmd(mdx-beta geo): a new allele for the mouse dystrophin gene.","date":"1998","source":"Developmental dynamics : an official publication of the American Association of Anatomists","url":"https://pubmed.ncbi.nlm.nih.gov/9626497","citation_count":56,"is_preprint":false},{"pmid":"32616572","id":"PMC_32616572","title":"Premature termination codons in the DMD gene cause reduced local mRNA synthesis.","date":"2020","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/32616572","citation_count":55,"is_preprint":false},{"pmid":"31594858","id":"PMC_31594858","title":"Relationships between DMD mutations and neurodevelopment in dystrophinopathy.","date":"2019","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/31594858","citation_count":53,"is_preprint":false},{"pmid":"15454965","id":"PMC_15454965","title":"Recombinant adeno-associated viral (rAAV) vectors as therapeutic tools for Duchenne muscular dystrophy (DMD).","date":"2004","source":"Gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/15454965","citation_count":51,"is_preprint":false},{"pmid":"29301272","id":"PMC_29301272","title":"Skipping Multiple Exons to Treat DMD-Promises and Challenges.","date":"2018","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/29301272","citation_count":49,"is_preprint":false},{"pmid":"34736624","id":"PMC_34736624","title":"The DMD gene and therapeutic approaches to restore dystrophin.","date":"2021","source":"Neuromuscular disorders : NMD","url":"https://pubmed.ncbi.nlm.nih.gov/34736624","citation_count":48,"is_preprint":false},{"pmid":"22555292","id":"PMC_22555292","title":"LINC complex alterations in DMD and EDMD/CMT fibroblasts.","date":"2012","source":"European journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/22555292","citation_count":47,"is_preprint":false},{"pmid":"34797383","id":"PMC_34797383","title":"Pharmacology and toxicology of eteplirsen and SRP-5051 for DMD exon 51 skipping: an update.","date":"2021","source":"Archives of toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/34797383","citation_count":43,"is_preprint":false},{"pmid":"27754374","id":"PMC_27754374","title":"Endogenous Multiple Exon Skipping and Back-Splicing at the DMD Mutation Hotspot.","date":"2016","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/27754374","citation_count":41,"is_preprint":false},{"pmid":"23536893","id":"PMC_23536893","title":"Interplay between DMD point mutations and splicing signals in Dystrophinopathy phenotypes.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23536893","citation_count":41,"is_preprint":false},{"pmid":"37858263","id":"PMC_37858263","title":"Myopathologic trajectory in Duchenne muscular dystrophy (DMD) reveals lack of regeneration due to senescence in satellite cells.","date":"2023","source":"Acta neuropathologica communications","url":"https://pubmed.ncbi.nlm.nih.gov/37858263","citation_count":40,"is_preprint":false},{"pmid":"28597072","id":"PMC_28597072","title":"Normal and altered pre-mRNA processing in the DMD gene.","date":"2017","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/28597072","citation_count":39,"is_preprint":false},{"pmid":"23975932","id":"PMC_23975932","title":"DMD transcript imbalance determines dystrophin levels.","date":"2013","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/23975932","citation_count":39,"is_preprint":false},{"pmid":"28390761","id":"PMC_28390761","title":"The AAV-mediated and RNA-guided CRISPR/Cas9 system for gene therapy of DMD and BMD.","date":"2017","source":"Brain & development","url":"https://pubmed.ncbi.nlm.nih.gov/28390761","citation_count":35,"is_preprint":false},{"pmid":"31416775","id":"PMC_31416775","title":"Exons 45-55 Skipping Using Mutation-Tailored Cocktails of Antisense Morpholinos in the DMD Gene.","date":"2019","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/31416775","citation_count":35,"is_preprint":false},{"pmid":"2570527","id":"PMC_2570527","title":"Hot spot of recombination within DXS164 in the Duchenne muscular dystrophy gene.","date":"1989","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/2570527","citation_count":34,"is_preprint":false},{"pmid":"20847377","id":"PMC_20847377","title":"Use of multiplex ligation-dependent probe amplification (MLPA) for Duchenne muscular dystrophy (DMD) gene mutation analysis.","date":"2010","source":"The Indian journal of medical research","url":"https://pubmed.ncbi.nlm.nih.gov/20847377","citation_count":33,"is_preprint":false},{"pmid":"22096509","id":"PMC_22096509","title":"Immune response and mitochondrial metabolism are commonly deregulated in DMD and aging skeletal muscle.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22096509","citation_count":31,"is_preprint":false},{"pmid":"2887110","id":"PMC_2887110","title":"Familial inheritance of a DXS164 deletion mutation from a heterozygous female.","date":"1987","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/2887110","citation_count":30,"is_preprint":false},{"pmid":"32241218","id":"PMC_32241218","title":"Common therapeutic advances for Duchenne muscular dystrophy (DMD).","date":"2020","source":"The International journal of neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/32241218","citation_count":30,"is_preprint":false},{"pmid":"27391342","id":"PMC_27391342","title":"Non-myogenic tumors display altered expression of dystrophin (DMD) and a high frequency of genetic alterations.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27391342","citation_count":30,"is_preprint":false},{"pmid":"25662218","id":"PMC_25662218","title":"FUBP1: a new protagonist in splicing regulation of the DMD gene.","date":"2015","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/25662218","citation_count":30,"is_preprint":false},{"pmid":"17726484","id":"PMC_17726484","title":"Simultaneous mutation scanning for gross deletions, duplications and point mutations in the DMD gene.","date":"2007","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/17726484","citation_count":29,"is_preprint":false},{"pmid":"32176650","id":"PMC_32176650","title":"Pseudoexons of the DMD Gene.","date":"2020","source":"Journal of neuromuscular diseases","url":"https://pubmed.ncbi.nlm.nih.gov/32176650","citation_count":28,"is_preprint":false},{"pmid":"31705731","id":"PMC_31705731","title":"Exonic rearrangements in DMD in Chinese Han individuals affected with Duchenne and Becker muscular dystrophies.","date":"2019","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/31705731","citation_count":25,"is_preprint":false},{"pmid":"33977140","id":"PMC_33977140","title":"WGS and RNA Studies Diagnose Noncoding DMD Variants in Males With High Creatine Kinase.","date":"2021","source":"Neurology. Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/33977140","citation_count":25,"is_preprint":false},{"pmid":"36320324","id":"PMC_36320324","title":"Prime editing optimized RTT permits the correction of the c.8713C>T mutation in DMD gene.","date":"2022","source":"Molecular therapy. Nucleic acids","url":"https://pubmed.ncbi.nlm.nih.gov/36320324","citation_count":25,"is_preprint":false},{"pmid":"33188007","id":"PMC_33188007","title":"Duchenne muscular dystrophy (DMD) cardiomyocyte-secreted exosomes promote the pathogenesis of DMD-associated cardiomyopathy.","date":"2020","source":"Disease models & mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/33188007","citation_count":25,"is_preprint":false},{"pmid":"35402069","id":"PMC_35402069","title":"Long-term maintenance of dystrophin expression and resistance to injury of skeletal muscle in gene edited DMD mice.","date":"2022","source":"Molecular therapy. Nucleic acids","url":"https://pubmed.ncbi.nlm.nih.gov/35402069","citation_count":24,"is_preprint":false},{"pmid":"31039133","id":"PMC_31039133","title":"Stabilization of the cardiac sarcolemma by sarcospan rescues DMD-associated cardiomyopathy.","date":"2019","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/31039133","citation_count":24,"is_preprint":false},{"pmid":"31197268","id":"PMC_31197268","title":"Maternal copy-number variations in the DMD gene as secondary findings in noninvasive prenatal screening.","date":"2019","source":"Genetics in medicine : official journal of the American College of Medical Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/31197268","citation_count":23,"is_preprint":false},{"pmid":"26030752","id":"PMC_26030752","title":"Dietary MicroRNA Database (DMD): An Archive Database and Analytic Tool for Food-Borne microRNAs.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26030752","citation_count":23,"is_preprint":false},{"pmid":"17981565","id":"PMC_17981565","title":"Clinical approaches in the treatment of Duchenne muscular dystrophy (DMD) using oligonucleotides.","date":"2008","source":"Frontiers in bioscience : a journal and virtual library","url":"https://pubmed.ncbi.nlm.nih.gov/17981565","citation_count":22,"is_preprint":false},{"pmid":"12206790","id":"PMC_12206790","title":"Gene transfer studies in animals: what do they really tell us about the prospects for gene therapy in DMD?","date":"2002","source":"Neuromuscular disorders : NMD","url":"https://pubmed.ncbi.nlm.nih.gov/12206790","citation_count":21,"is_preprint":false},{"pmid":"35024902","id":"PMC_35024902","title":"Current Practices in Treating Cardiomyopathy and Heart Failure in Duchenne Muscular Dystrophy (DMD): Understanding Care Practices in Order to Optimize DMD Heart Failure Through ACTION.","date":"2022","source":"Pediatric cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/35024902","citation_count":21,"is_preprint":false},{"pmid":"36252992","id":"PMC_36252992","title":"Cardiac care of children with dystrophinopathy and females carrying DMD-gene variations.","date":"2022","source":"Open heart","url":"https://pubmed.ncbi.nlm.nih.gov/36252992","citation_count":20,"is_preprint":false},{"pmid":"38596212","id":"PMC_38596212","title":"The complex landscape of DMD mutations: moving towards personalized medicine.","date":"2024","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/38596212","citation_count":20,"is_preprint":false},{"pmid":"30833962","id":"PMC_30833962","title":"Genotypes and Phenotypes of DMD Small Mutations in Chinese Patients With Dystrophinopathies.","date":"2019","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/30833962","citation_count":20,"is_preprint":false},{"pmid":"32417793","id":"PMC_32417793","title":"Clinical Phenotypes of DMD Exon 51 Skip Equivalent Deletions: A Systematic Review.","date":"2020","source":"Journal of neuromuscular diseases","url":"https://pubmed.ncbi.nlm.nih.gov/32417793","citation_count":20,"is_preprint":false},{"pmid":"31628052","id":"PMC_31628052","title":"The SINE Compound KPT-350 Blocks Dystrophic Pathologies in DMD Zebrafish and Mice.","date":"2019","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/31628052","citation_count":19,"is_preprint":false},{"pmid":"35615378","id":"PMC_35615378","title":"Long-Read Sequencing Revealed Extragenic and Intragenic Duplications of Exons 56-61 in DMD in an Asymptomatic Male and a DMD Patient.","date":"2022","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/35615378","citation_count":19,"is_preprint":false},{"pmid":"36588820","id":"PMC_36588820","title":"Correction of DMD in human iPSC-derived cardiomyocytes by base-editing-induced exon skipping.","date":"2022","source":"Molecular therapy. Methods & clinical development","url":"https://pubmed.ncbi.nlm.nih.gov/36588820","citation_count":18,"is_preprint":false},{"pmid":"27215286","id":"PMC_27215286","title":"The emerging role of viral vectors as vehicles for DMD gene editing.","date":"2016","source":"Genome medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27215286","citation_count":18,"is_preprint":false},{"pmid":"35912688","id":"PMC_35912688","title":"Detection of pericentric inversion with breakpoint in DMD by whole genome sequencing.","date":"2022","source":"Molecular genetics & genomic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35912688","citation_count":17,"is_preprint":false},{"pmid":"26159373","id":"PMC_26159373","title":"Adeno-Associated Virus (AAV) Mediated Dystrophin Gene Transfer Studies and Exon Skipping Strategies for Duchenne Muscular Dystrophy (DMD).","date":"2015","source":"Current gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/26159373","citation_count":16,"is_preprint":false},{"pmid":"19783145","id":"PMC_19783145","title":"Point mutations in Czech DMD/BMD patients and their phenotypic outcome.","date":"2009","source":"Neuromuscular disorders : NMD","url":"https://pubmed.ncbi.nlm.nih.gov/19783145","citation_count":16,"is_preprint":false},{"pmid":"26972252","id":"PMC_26972252","title":"Structural characterizations of phage antitoxin Dmd and its interactions with bacterial toxin RnlA.","date":"2016","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/26972252","citation_count":16,"is_preprint":false},{"pmid":"37819629","id":"PMC_37819629","title":"Comparison of pharmaceutical properties and biological activities of prednisolone, deflazacort, and vamorolone in DMD disease models.","date":"2024","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/37819629","citation_count":15,"is_preprint":false},{"pmid":"37671549","id":"PMC_37671549","title":"DMD-Associated Dilated Cardiomyopathy: Genotypes, Phenotypes, and Phenocopies.","date":"2023","source":"Circulation. Genomic and precision medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37671549","citation_count":15,"is_preprint":false},{"pmid":"36198806","id":"PMC_36198806","title":"Identification and characterization of two DMD pedigrees with large inversion mutations based on a long-read sequencing pipeline.","date":"2022","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/36198806","citation_count":15,"is_preprint":false},{"pmid":"36360209","id":"PMC_36360209","title":"Reclassification of DMD Duplications as Benign: Recommendations for Cautious Interpretation of Variants Identified in Prenatal Screening.","date":"2022","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/36360209","citation_count":15,"is_preprint":false},{"pmid":"31266185","id":"PMC_31266185","title":"Recurrent DMD Deletions Highlight Specific Role of Dp71 Isoform in Soft-Tissue Sarcomas.","date":"2019","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/31266185","citation_count":15,"is_preprint":false},{"pmid":"34266495","id":"PMC_34266495","title":"Pathological alterations in the gastrointestinal tract of a porcine model of DMD.","date":"2021","source":"Cell & bioscience","url":"https://pubmed.ncbi.nlm.nih.gov/34266495","citation_count":15,"is_preprint":false},{"pmid":"33376799","id":"PMC_33376799","title":"Ethnicity-related DMD Genotype Landscapes in European and Non-European Countries.","date":"2020","source":"Neurology. Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/33376799","citation_count":14,"is_preprint":false},{"pmid":"18853462","id":"PMC_18853462","title":"Transcriptional behavior of DMD gene duplications in DMD/BMD males.","date":"2009","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/18853462","citation_count":14,"is_preprint":false},{"pmid":"29776718","id":"PMC_29776718","title":"High urinary ferritin reflects myoglobin iron evacuation in DMD patients.","date":"2018","source":"Neuromuscular disorders : NMD","url":"https://pubmed.ncbi.nlm.nih.gov/29776718","citation_count":14,"is_preprint":false},{"pmid":"39499670","id":"PMC_39499670","title":"Natural history of Becker muscular dystrophy: DMD gene mutations predict clinical severity.","date":"2025","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/39499670","citation_count":12,"is_preprint":false},{"pmid":"31130422","id":"PMC_31130422","title":"Pulmonary function and clinical correlation in DMD.","date":"2018","source":"Paediatric respiratory reviews","url":"https://pubmed.ncbi.nlm.nih.gov/31130422","citation_count":12,"is_preprint":false},{"pmid":"35897138","id":"PMC_35897138","title":"Dystrophinopathy Phenotypes and Modifying Factors in DMD Exon 45-55 Deletion.","date":"2022","source":"Annals of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/35897138","citation_count":12,"is_preprint":false},{"pmid":"38702481","id":"PMC_38702481","title":"Severe cardiac and skeletal manifestations in DMD-edited microminipigs: an advanced surrogate for Duchenne muscular dystrophy.","date":"2024","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/38702481","citation_count":12,"is_preprint":false},{"pmid":"36319768","id":"PMC_36319768","title":"Clinical, muscle imaging, and genetic characteristics of dystrophinopathies with deep-intronic DMD variants.","date":"2022","source":"Journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/36319768","citation_count":12,"is_preprint":false},{"pmid":"37501163","id":"PMC_37501163","title":"IPSC derived cardiac fibroblasts of DMD patients show compromised actin microfilaments, metabolic shift and pro-fibrotic phenotype.","date":"2023","source":"Biology direct","url":"https://pubmed.ncbi.nlm.nih.gov/37501163","citation_count":12,"is_preprint":false},{"pmid":"26932192","id":"PMC_26932192","title":"Comparative transcriptome analysis of muscular dystrophy models Large(myd), Dmd(mdx)/Large(myd) and Dmd(mdx): what makes them different?","date":"2016","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/26932192","citation_count":12,"is_preprint":false},{"pmid":"37305116","id":"PMC_37305116","title":"Prime editing strategies to mediate exon skipping in DMD gene.","date":"2023","source":"Frontiers in medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37305116","citation_count":11,"is_preprint":false},{"pmid":"37625413","id":"PMC_37625413","title":"Dual CRISPR-Cas3 system for inducing multi-exon skipping in DMD patient-derived iPSCs.","date":"2023","source":"Stem cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/37625413","citation_count":11,"is_preprint":false},{"pmid":"38891104","id":"PMC_38891104","title":"A Novel CRISPR-Cas9 Strategy to Target DYSTROPHIN Mutations Downstream of Exon 44 in Patient-Specific DMD iPSCs.","date":"2024","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/38891104","citation_count":11,"is_preprint":false},{"pmid":"25131993","id":"PMC_25131993","title":"MLPA Application in Clinical Diagnosis of DMD/BMD in Shanghai.","date":"2014","source":"Journal of clinical laboratory analysis","url":"https://pubmed.ncbi.nlm.nih.gov/25131993","citation_count":11,"is_preprint":false},{"pmid":"32655290","id":"PMC_32655290","title":"Repurposing Pathogenic Variants of DMD Gene and its Isoforms for DMD Exon Skipping Intervention.","date":"2019","source":"Current genomics","url":"https://pubmed.ncbi.nlm.nih.gov/32655290","citation_count":10,"is_preprint":false},{"pmid":"27858746","id":"PMC_27858746","title":"MicroRNA and mRNA Expression Changes in Steroid Naïve and Steroid Treated DMD Patients.","date":"2015","source":"Journal of neuromuscular diseases","url":"https://pubmed.ncbi.nlm.nih.gov/27858746","citation_count":10,"is_preprint":false},{"pmid":"39607794","id":"PMC_39607794","title":"Long-Term Survival and Myocardial Function Following Systemic Delivery of Delandistrogene Moxeparvovec in DMDMDX Rats.","date":"2024","source":"Human gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/39607794","citation_count":10,"is_preprint":false},{"pmid":"31661024","id":"PMC_31661024","title":"The analysis of DMD gene deletions by multiplex PCR in Indonesian DMD/BMD patients: the era of personalized medicine.","date":"2019","source":"BMC research notes","url":"https://pubmed.ncbi.nlm.nih.gov/31661024","citation_count":10,"is_preprint":false},{"pmid":"20382434","id":"PMC_20382434","title":"Differential integrin expression by T lymphocytes: potential role in DMD muscle damage.","date":"2010","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/20382434","citation_count":10,"is_preprint":false},{"pmid":"33936175","id":"PMC_33936175","title":"Novel Intronic Mutations Introduce Pseudoexons in DMD That Cause Muscular Dystrophy in Patients.","date":"2021","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/33936175","citation_count":10,"is_preprint":false},{"pmid":"29201118","id":"PMC_29201118","title":"Duchenne Muscular Dystrophy (DMD) Protein-Protein Interaction Mapping.","date":"2017","source":"Iranian journal of child neurology","url":"https://pubmed.ncbi.nlm.nih.gov/29201118","citation_count":9,"is_preprint":false},{"pmid":"35143959","id":"PMC_35143959","title":"Comparison of dystrophin expression following gene editing and gene replacement in an aged preclinical DMD animal model.","date":"2022","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/35143959","citation_count":9,"is_preprint":false},{"pmid":"39596689","id":"PMC_39596689","title":"An Updated Analysis of Exon-Skipping Applicability for Duchenne Muscular Dystrophy Using the UMD-DMD Database.","date":"2024","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/39596689","citation_count":9,"is_preprint":false},{"pmid":"29766838","id":"PMC_29766838","title":"DMD mutation and LTBP4 haplotype do not predict onset of left ventricular dysfunction in Duchenne muscular dystrophy.","date":"2018","source":"Cardiology in the young","url":"https://pubmed.ncbi.nlm.nih.gov/29766838","citation_count":9,"is_preprint":false},{"pmid":"31737793","id":"PMC_31737793","title":"Schwann cell-specific Dp116 is expressed in glioblastoma cells, revealing two novel DMD gene splicing patterns.","date":"2019","source":"Biochemistry and biophysics reports","url":"https://pubmed.ncbi.nlm.nih.gov/31737793","citation_count":9,"is_preprint":false},{"pmid":"38137463","id":"PMC_38137463","title":"Networking to Optimize Dmd exon 53 Skipping in the Brain of mdx52 Mouse Model.","date":"2023","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/38137463","citation_count":9,"is_preprint":false},{"pmid":"36873982","id":"PMC_36873982","title":"Vascular therapy for Duchenne muscular dystrophy (DMD).","date":"2023","source":"Faculty reviews","url":"https://pubmed.ncbi.nlm.nih.gov/36873982","citation_count":8,"is_preprint":false},{"pmid":"36041985","id":"PMC_36041985","title":"Tandem duplication within the DMD gene in Labrador retrievers with a mild clinical phenotype.","date":"2022","source":"Neuromuscular disorders : NMD","url":"https://pubmed.ncbi.nlm.nih.gov/36041985","citation_count":8,"is_preprint":false},{"pmid":"36834603","id":"PMC_36834603","title":"Dystrophin (DMD) Missense Variant in Cats with Becker-Type Muscular Dystrophy.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36834603","citation_count":8,"is_preprint":false},{"pmid":"37626761","id":"PMC_37626761","title":"Characterization of the Ang/Tie2 Signaling Pathway in the Diaphragm Muscle of DMD Mice.","date":"2023","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/37626761","citation_count":8,"is_preprint":false},{"pmid":"36012442","id":"PMC_36012442","title":"Full-Length Dystrophin Restoration via Targeted Exon Addition in DMD-Patient Specific iPSCs and Cardiomyocytes.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36012442","citation_count":8,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":46532,"output_tokens":5122,"usd":0.108213,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":13641,"output_tokens":3839,"usd":0.08209,"stage2_stop_reason":"end_turn"},"total_usd":0.190303,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1989,\n      \"finding\": \"Frameshift deletions in the DMD gene result in more severe (Duchenne) phenotype than in-frame deletions, which result in milder (Becker) phenotype. This 'reading frame rule' was established by correlating deletion endpoints (determined by genomic probes) with clinical phenotype in 80 unrelated patients.\",\n      \"method\": \"Genomic deletion mapping with cDNA probes and clinical phenotype correlation in 80 patients\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — large cohort genotype-phenotype correlation replicated across multiple labs, foundational reading frame rule established\",\n      \"pmids\": [\"2491010\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"The H19 differentially methylated domain (DMD) acts as a maternal-specific, methylation-sensitive insulator by binding CTCF on the maternal allele. CpG mutations in the DMD repeats that retain CTCF-binding and enhancer-blocking activity disrupted maintenance of paternal DMD methylation in vivo, demonstrating that CpG content of the repeats is required for methylation maintenance but is antagonistic to insulator assembly. NOTE: This paper concerns the H19-Igf2 imprinting control region DMD (differentially methylated domain), not the dystrophin protein-coding DMD gene.\",\n      \"method\": \"CpG point mutagenesis of the H19 DMD in mice, maternal/paternal inheritance analysis, reporter gene expression\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 1 / Strong — rigorous in vivo mutagenesis, but this paper concerns the H19 imprinting locus 'DMD', not the dystrophin gene; excluded from canonical protein mechanism\",\n      \"pmids\": [\"15273688\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Duplication mutations in the DMD gene arise predominantly near the 5' end of the gene (exon 2 being the most common single duplication), and sequencing of breakpoints showed they do not arise from unequal sister chromatid exchange but more likely from synthesis-dependent nonhomologous end joining, indicating a distinct mutational mechanism from deletions.\",\n      \"method\": \"MLPA, breakpoint sequencing, analysis of 118 DMD duplications\",\n      \"journal\": \"Human mutation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — breakpoint sequencing in 118 cases from a single study, two orthogonal methods\",\n      \"pmids\": [\"16917894\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Transgenic mice carrying the intact full-length human DMD gene (hDMD) express all dystrophin isoforms in a tissue-specific pattern consistent with the endogenous gene. The hDMD transgene rescued the lethal dystrophic phenotype of mdx x utrophin-null mice, demonstrating functional competence of the human genomic locus in vivo.\",\n      \"method\": \"Yeast artificial chromosome fusion, transgenic mouse generation, RT-PCR, Western blotting, histological analysis, genetic rescue of mdx x Utrn-/- mice\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — functional in vivo rescue of lethal phenotype with full-length human gene, multiple orthogonal validation methods\",\n      \"pmids\": [\"18083704\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Duplications in the DMD gene can produce aberrant transcripts that do not follow simple reading-frame predictions; RNA analysis revealed that exon-skipping events occurring within duplicated regions can re-establish the reading frame in some BMD patients carrying out-of-frame duplications, while an in-frame duplication can cause DMD through post-transcriptional/translational mechanisms not explained by the reading frame rule.\",\n      \"method\": \"RNA analysis (RT-PCR) of duplicated DMD transcripts in 16 patients\",\n      \"journal\": \"Human mutation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct RNA analysis in patients, single lab, two orthogonal findings\",\n      \"pmids\": [\"18853462\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"The DMD gene is more highly expressed in heart than in skeletal muscle. Transcript stability (rather than transcriptional rate) is an important determinant of dystrophin protein levels in Becker muscular dystrophy patients. The mdx mouse mutant transcript shows a 5' to 3' imbalance compared to wild-type, and antisense-mediated exon skipping does not correct this imbalance.\",\n      \"method\": \"RT-PCR quantification, Western blotting, antisense exon-skipping experiments in mice and human patients\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple methods (RT-PCR, Western blot, exon skipping experiments), single lab\",\n      \"pmids\": [\"23975932\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"DMD point mutations can alter splicing regulatory elements (exonic splicing silencers/enhancers) to cause exon skipping, modifying disease severity. Nonsense and frameshift point mutations can produce aberrant splicing in 27/98 analyzed cases. Bioinformatics analysis showed the splicing pathway is highly dependent on the interplay between splice site strength and density of regulatory elements.\",\n      \"method\": \"RNA analysis of muscle mRNA, dystrophin protein expression, bioinformatics analysis of splicing signals in 98 DMD point mutation patients\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct mRNA analysis in patient samples, large cohort, single lab\",\n      \"pmids\": [\"23536893\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"FUSE binding protein 1 (FUBP1) promotes recognition of endogenous DMD exon 39 in muscle cells by binding to an intronic splicing enhancer (ISE) in intron 38. RNase-assisted pulldown with mass spectrometry revealed that hnRNPA1, hnRNPA2/B1, and DAZAP1 are recruited to a mutant RNA probe and act as splicing repressors of exon 39. FUBP1 binding to the ISE RNA was confirmed by RNA pulldown, RNA EMSA, and RNA-ChIP on endogenous DMD pre-mRNA.\",\n      \"method\": \"RNase-assisted RNA pulldown with mass spectrometry, minigene splicing assays, RNA EMSA, RNA-ChIP, serial deletion and mutagenesis\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple orthogonal methods (pulldown-MS, EMSA, RNA-ChIP, mutagenesis) in a single rigorous study identifying mechanism of DMD pre-mRNA splicing regulation\",\n      \"pmids\": [\"25662218\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Endogenous multiple exon skipping (MES) products are present in normal human skeletal muscle RNA around the exon 44-56 region of the DMD gene. The 5' splice sites of post-transcriptional introns act as splicing donor sites for MES events. Upstream post-transcriptional introns trigger MES and generate circular RNAs (circRNAs) via back-splicing, consistent with the circRNA generation model.\",\n      \"method\": \"RT-PCR of total RNA from normal skeletal muscle, identification and sequencing of MES products, circular RNA analysis\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct RNA analysis in human tissue, single lab, multiple orthogonal findings\",\n      \"pmids\": [\"27754374\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"DMD pre-mRNA splicing requires multi-step events for removal of long introns, involving temporary intron retention and co-transcriptional mechanisms. The large size of DMD introns necessitates recursive (multi-step) splicing, and alternative splicing can serve as a disease modifier by changing the outcome of primary mutations.\",\n      \"method\": \"Review synthesizing RNA sequencing data and splicing studies on human skeletal muscle DMD pre-mRNA\",\n      \"journal\": \"Human genetics\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — review paper summarizing experimental findings from multiple sources, no single direct experiment described in this abstract\",\n      \"pmids\": [\"28597072\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Dp71, the short dystrophin isoform expressed from a promoter in DMD intron 62, plays an essential role in tumor cell proliferation and clonogenicity in soft-tissue sarcomas. Dp71 inhibition by shRNA dramatically reduced cell proliferation and clonogenicity by altering cell cycle progression through G2/M phase, whereas Dp427 depletion had no effect on cell growth or migration.\",\n      \"method\": \"shRNA knockdown of Dp71 in STS cell lines, cell proliferation and clonogenicity assays, cell cycle analysis, RNA sequencing\",\n      \"journal\": \"Cancers\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function with defined cell cycle phenotype in three STS cell lines, single lab\",\n      \"pmids\": [\"31266185\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"DMD cardiomyocyte-secreted exosomes (DMD-exo) promote pathological vulnerability to stress in DMD cardiomyocytes. The microRNA cargo (not surface peptides) of DMD-exo was implicated in pathological effects, with DMD-exo miRNA cargo regulating injurious pathways including p53 and TGF-beta. Non-affected exosomes were protective, while DMD-exo were not, and inhibition of DMD-exo secretion in vitro and in vivo improved stress response.\",\n      \"method\": \"iPSC-derived cardiomyocytes, exosome isolation and characterization, miRNA cargo profiling, transcriptomic profiling, ROS measurement, mitochondrial membrane potential assay, in vivo exosome secretion inhibition\",\n      \"journal\": \"Disease models & mechanisms\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods in iPSC-derived cardiomyocytes and in vivo, single lab\",\n      \"pmids\": [\"33188007\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Sarcospan (SSPN) overexpression restores cardiac sarcolemma stability in dystrophin-deficient mdx mice. SSPN interacts with dystrophin and utrophin at the sarcolemma and, when overexpressed, enhances fully glycosylated α-dystroglycan abundance, restores sarcolemmal stability (primary defect in DMD), reduces fibrosis, and improves cardiac contractile function and β-adrenergic responsiveness.\",\n      \"method\": \"SSPN transgenic mice crossed to mdx and mdx:utr-heterozygous backgrounds, echocardiography, hemodynamic pressure-volume analysis, histology, biochemical analysis\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple cardiac functional readouts in transgenic animal model, single lab, mechanistic link to sarcolemma stability\",\n      \"pmids\": [\"31039133\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"In a canine DMD model with dystrophin deficiency (CXMD), inactivating mutations in the DMD gene occur frequently, and DMD is recurrently somatically mutated/deleted in canine osteosarcoma (50% of tumors). This suggests a tumor suppressor role for dystrophin beyond myogenic tissues.\",\n      \"method\": \"Whole genome sequencing and whole exome sequencing of 59 canine osteosarcoma tumors with matched normal tissue\",\n      \"journal\": \"Communications biology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — genomic sequencing study, no direct functional experiment on the DMD protein mechanism\",\n      \"pmids\": [\"31341965\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"A tandem duplication involving DMD exons 2-7 inserted into intron 7 of the wild-type DMD gene in Labrador retrievers results in dystrophin non-detectable by Western blot and immunohistochemistry, but α-dystroglycan is present at essentially normal levels, indicating that α-dystroglycan membrane localization does not absolutely require dystrophin in this model.\",\n      \"method\": \"Whole genome sequencing, skeletal muscle cDNA analysis, Western blotting for dystrophin and α-dystroglycan, immunohistochemistry\",\n      \"journal\": \"Neuromuscular disorders : NMD\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct protein biochemistry (Western blot) in a natural animal model with defined mutation, single report\",\n      \"pmids\": [\"36041985\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"The Dp116 isoform of dystrophin, expressed from a promoter in DMD intron 55, is expressed in glioblastoma cells. Two novel splicing patterns of DMD exons within the Dp116 region were identified: deletion of exons 68-69 and a 5' cryptic splice acceptor in exon 75, in addition to the predominant Dp116b variant lacking exon 78.\",\n      \"method\": \"PCR amplification of full-length Dp116 cDNA from U-251 glioblastoma cells, Western blotting, cDNA sequencing\",\n      \"journal\": \"Biochemistry and biophysics reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct RT-PCR and Western blot characterization of isoform expression, novel splice variants identified by sequencing, single lab\",\n      \"pmids\": [\"31737793\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Premature termination codons (PTCs) in the DMD gene reduce local DMD mRNA synthesis through a transcriptional (not NMD-based cytoplasmic) mechanism. NMD inhibition did not normalize DMD expression. In situ hybridization showed DMD mRNA localizes primarily in the nuclear compartment, ruling out cytoplasmic NMD. Nascent RNA sequencing revealed lower transcription rate in patient-derived myotubes. Chromatin immunoprecipitation showed increased H3K9me3 (repressive histone mark) at the DMD locus in mdx mice, and HDAC inhibitor givinostat increased DMD transcript expression in mdx mice.\",\n      \"method\": \"NMD inhibition assay, in situ hybridization, nascent RNA sequencing, chromatin immunoprecipitation (ChIP) for H3K9me3, HDAC inhibitor treatment in mdx mice\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple orthogonal methods (NMD inhibition, in situ hybridization, nascent RNA-seq, ChIP, pharmacological rescue) in a single study establishing epigenetic mechanism\",\n      \"pmids\": [\"32616572\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Noncoding (deep intronic) DMD variants cause splice-altering events leading to premature stop codons and nonsense-mediated mRNA decay. Quantitative Western blot correlated wild-type dystrophin levels with clinical severity: 0-5% dystrophin confers Duchenne phenotype, ~10% confers Becker phenotype, and ~15% is associated with myalgia without manifesting weakness.\",\n      \"method\": \"Whole-genome sequencing, muscle RNA-seq, PCR of muscle cDNA, quantitative Western blot for dystrophin\",\n      \"journal\": \"Neurology. Genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — quantitative Western blot linked to clinical phenotype in multiple families, single lab, consistent with prior literature\",\n      \"pmids\": [\"33977140\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Loss of full-length dystrophin isoform in hiPSC-derived cardiac fibroblasts from DMD patients results in deficient formation of actin microfilaments and a metabolic switch from mitochondrial oxidation to glycolysis. This metabolic remodeling is associated with an exacerbated myofibroblast phenotype and increased fibroblast activation in response to pro-fibrotic challenges.\",\n      \"method\": \"hiPSC-derived cardiac fibroblasts from DMD patients, immunofluorescence for actin microfilaments, mitochondrial respiration assay (Seahorse), glycolysis measurement, myofibroblast activation assay\",\n      \"journal\": \"Biology direct\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (cytoskeletal, metabolic, phenotypic assays) in patient-derived cells, single lab\",\n      \"pmids\": [\"37501163\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"In DMD skeletal muscle, fibro-adipogenic progenitor (FAP) content increases concurrently with a decline in muscle regenerative capacity. DMD muscle stem cells acquire a senescence phenotype early in the disease course, and this senescence correlates with impaired satellite cell activation and expansion.\",\n      \"method\": \"Myopathologic analysis of 24 DMD patient muscle biopsies, immunostaining and histology for FAPs, satellite cells, and senescence markers\",\n      \"journal\": \"Acta neuropathologica communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct histopathological analysis in patient biopsies with cellular mechanistic readouts, single lab\",\n      \"pmids\": [\"37858263\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"The DMD gene encodes dystrophin, a large cytoskeletal protein whose absence (caused by frame-disrupting mutations) leads to loss of sarcolemmal stability; the reading frame rule governs phenotypic severity (frameshift = Duchenne, in-frame = Becker), with transcript stability and chromatin-level epigenetic repression (H3K9me3) further determining residual dystrophin levels; pre-mRNA splicing of the large DMD transcript involves co-transcriptional recursive splicing regulated by intronic enhancers bound by FUBP1 and repressors including hnRNPA1/A2B1; the short Dp71 isoform has an independent role in cell cycle progression in non-muscle cells; and dystrophin deficiency in cardiomyocytes propagates pathological signals via exosomal miRNA cargo, while loss of full-length dystrophin in cardiac fibroblasts disrupts actin microfilaments and drives metabolic reprogramming toward glycolysis with a pro-fibrotic phenotype.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"The DMD gene encodes dystrophin, a cytoskeletal protein required for sarcolemmal stability whose loss underlies Duchenne and Becker muscular dystrophy [#0, #12]. Frame-disrupting mutations follow a reading-frame rule in which frameshift deletions cause severe Duchenne phenotypes while in-frame deletions cause milder Becker disease [#0], and residual dystrophin levels quantitatively track clinical severity, with 0–5% conferring Duchenne, ~10% Becker, and ~15% only myalgia [#17]. The functional competence of the full-length human locus is established by transgenic rescue of the lethal mdx × utrophin-null dystrophic phenotype [#3]. At the membrane, dystrophin acts with sarcospan and utrophin to maintain glycosylated α-dystroglycan and sarcolemmal integrity, the primary defect in DMD, with sarcospan overexpression restoring cardiac stability and contractile function in dystrophin-deficient hearts [#12]. The exceptionally large DMD pre-mRNA undergoes multi-step recursive, co-transcriptional splicing in which intronic enhancers recruit FUBP1 to promote exon recognition while hnRNPA1, hnRNPA2/B1 and DAZAP1 act as splicing repressors [#7], and splicing outcomes — including point-mutation-induced exon skipping and endogenous multiple-exon-skipping that generates circular RNAs — serve as disease modifiers [#6, #8]. Beyond splicing, dystrophin expression is regulated transcriptionally and epigenetically: premature termination codons reduce nascent transcription rather than triggering cytoplasmic NMD, accompanied by repressive H3K9me3 deposition at the locus that is relieved by HDAC inhibition [#16]. Internal promoters generate shorter isoforms with distinct roles, including Dp71, which drives sarcoma cell proliferation through G2/M cell cycle progression [#10]. Dystrophin deficiency also has non-myofiber consequences: cardiomyocyte-secreted exosomal miRNA cargo propagates pathological stress signaling via p53 and TGF-β pathways [#11], cardiac fibroblasts lose actin microfilaments and undergo a glycolytic, pro-fibrotic metabolic switch [#18], and muscle stem cells acquire early senescence with expansion of fibro-adipogenic progenitors [#19].\",\n  \"teleology\": [\n    {\n      \"year\": 1989,\n      \"claim\": \"Established the genotype-phenotype logic of DMD by showing that whether a deletion preserves the translational reading frame, not its size, determines disease severity.\",\n      \"evidence\": \"Genomic deletion mapping with cDNA probes correlated to clinical phenotype in 80 patients\",\n      \"pmids\": [\"2491010\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not explain exceptions where in-frame mutations cause severe disease\", \"No molecular mechanism for how truncated protein retains partial function\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Resolved the mutational origin of DMD duplications, showing they cluster at the 5' end and arise by synthesis-dependent nonhomologous end joining rather than unequal sister chromatid exchange.\",\n      \"evidence\": \"MLPA and breakpoint sequencing of 118 DMD duplications\",\n      \"pmids\": [\"16917894\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-study cohort\", \"Does not link breakpoint mechanism to phenotypic outcome\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Demonstrated that the full-length human DMD genomic locus is functionally competent in vivo, rescuing the lethal dystrophic phenotype and providing a humanized model.\",\n      \"evidence\": \"Full-length hDMD transgenic mouse, genetic rescue of mdx × Utrn-/- mice with RT-PCR, Western blot, histology\",\n      \"pmids\": [\"18083704\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not dissect individual isoform contributions to rescue\", \"No quantitative threshold for rescue established\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Revealed exceptions to the reading-frame rule by showing that exon-skipping within duplications can restore frame and that in-frame duplications can still cause disease through post-transcriptional mechanisms.\",\n      \"evidence\": \"RT-PCR RNA analysis of duplicated DMD transcripts in 16 patients\",\n      \"pmids\": [\"18853462\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Small patient number\", \"Post-transcriptional mechanism for in-frame duplication pathogenicity not defined\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Identified transcript stability and splicing-regulatory point mutations as quantitative determinants of dystrophin levels beyond simple frame prediction.\",\n      \"evidence\": \"RT-PCR, Western blot, exon-skipping in mdx/patients; RNA and bioinformatic splicing analysis of 98 point-mutation patients\",\n      \"pmids\": [\"23975932\", \"23536893\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism controlling transcript stability not identified\", \"Splicing predictions not validated for all mutation classes\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Defined the protein machinery of DMD pre-mRNA splicing, identifying FUBP1 as an intronic-enhancer-bound activator of exon recognition antagonized by hnRNP repressors.\",\n      \"evidence\": \"RNase-assisted pulldown-MS, minigene assays, RNA EMSA, RNA-ChIP, mutagenesis on endogenous DMD pre-mRNA\",\n      \"pmids\": [\"25662218\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Studied at a single exon (exon 39); generality across the transcript unknown\", \"How these factors are deployed across recursive splicing not addressed\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Showed that endogenous multiple-exon-skipping and back-splicing generate circular RNAs from the DMD transcript, revealing complexity in normal DMD processing.\",\n      \"evidence\": \"RT-PCR and sequencing of MES products and circRNAs from normal human skeletal muscle\",\n      \"pmids\": [\"27754374\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Function of DMD circRNAs unknown\", \"Single-tissue analysis\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Overturned the assumption that nonsense mutations act only via cytoplasmic NMD, showing instead a transcriptional/epigenetic mechanism marked by H3K9me3 that is pharmacologically reversible.\",\n      \"evidence\": \"NMD inhibition, in situ hybridization, nascent RNA-seq, H3K9me3 ChIP, givinostat treatment in mdx mice\",\n      \"pmids\": [\"32616572\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism linking PTC to chromatin repression not defined\", \"Whether givinostat-induced transcript yields functional protein not shown\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Quantified the dystrophin-level thresholds separating Duchenne, Becker, and asymptomatic-myalgia phenotypes, and showed deep-intronic variants cause disease via splice-altering NMD.\",\n      \"evidence\": \"Whole-genome sequencing, muscle RNA-seq, cDNA PCR, quantitative Western blot across families\",\n      \"pmids\": [\"33977140\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Thresholds derived from limited families\", \"Does not address tissue-specific level requirements\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Established roles for dystrophin and its isoforms beyond myofiber structure, including Dp71-driven sarcoma proliferation, exosomal miRNA-mediated cardiac stress signaling, and sarcospan-dependent sarcolemmal stabilization.\",\n      \"evidence\": \"shRNA Dp71 knockdown with cell-cycle/RNA-seq analysis; iPSC-cardiomyocyte exosome and miRNA profiling with in vivo inhibition; SSPN transgenic mdx cardiac functional analysis\",\n      \"pmids\": [\"31266185\", \"33188007\", \"31039133\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Dp71 cell-cycle mechanism molecularly undefined\", \"Specific causal exosomal miRNAs not pinpointed\", \"Sarcospan findings are overexpression-based\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Extended DMD pathology to non-myofiber cell types, showing dystrophin loss drives cardiac fibroblast metabolic reprogramming/fibrosis and muscle stem-cell senescence with FAP expansion.\",\n      \"evidence\": \"hiPSC-derived cardiac fibroblast cytoskeletal/metabolic assays; myopathologic and immunostaining analysis of 24 patient muscle biopsies\",\n      \"pmids\": [\"37501163\", \"37858263\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Causal link between actin loss and glycolytic switch not mechanistically resolved\", \"Senescence trigger in stem cells unidentified\", \"Single-lab patient cohorts\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How dystrophin isoform-specific functions, recursive co-transcriptional splicing, epigenetic repression, and non-myofiber pathology integrate into a unified disease mechanism remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural model of dystrophin in the sarcolemmal complex from the corpus\", \"Molecular partners of short isoforms in non-muscle cells unmapped\", \"Whether transcript-level interventions restore functional protein at disease thresholds untested\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0008092\", \"supporting_discovery_ids\": [12, 18]},\n      {\"term_id\": \"GO:0005198\", \"supporting_discovery_ids\": [3, 12]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [12, 14]},\n      {\"term_id\": \"GO:0005856\", \"supporting_discovery_ids\": [18]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0008953854\", \"supporting_discovery_ids\": [7]}\n    ],\n    \"complexes\": [\"dystrophin-glycoprotein complex\"],\n    \"partners\": [\"SSPN\", \"UTRN\", \"FUBP1\", \"HNRNPA1\", \"HNRNPA2B1\", \"DAZAP1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}